Odronextamab Biosimilar - Research Grade

Human

CD3 + CD20

>1mg/ml

Human IgG4

Glofitamab Biosimilar - Research Grade (ICH5019)

https://www.imgt.org/mAb-DB/

ICH3002

P07766;P11836

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of odronextamab, supplied for research use only. Odronextamab is a CD3xCD20 bispecific antibody: one arm engages CD3 on T cells while the other binds CD20 on B cells, redirecting T-cell cytotoxicity toward CD20-positive targets. The research-grade analog is built around this dual-targeting design on a human IgG4 framework and is intended as a laboratory tool, not as the clinical product; it is not for human or veterinary use. It is useful for in-vitro characterization of T-cell-engaging bispecific biology, as a positive control or benchmark in binding and cytotoxicity assays, for reagent development (including screening cascades and assay standardization), and for preclinical method development. It is offered in bulk milligram-to-gram quantities with low-endotoxin research grade (below 1 EU/mg) and ultra-low-endotoxin (below 0.5 EU/mg) options, supporting cell-based and sensitive downstream work where endotoxin control matters. No clone identity is implied; the reagent is defined by its dual specificity and format. Odronextamab has dual specificity against CD3 and CD20. CD3 (here the epsilon subunit, UniProt P07766) is part of the CD3-TCR complex on T cells; the CD3 gamma, delta, epsilon and zeta chains transduce antigen-recognition signals through ITAMs, and engaging CD3 with a bispecific antibody can trigger T-cell activation independent of native TCR-peptide-MHC recognition. CD20 (MS4A1, UniProt P11836) is a four-transmembrane B-cell surface protein of the MS4A family, expressed from pre-B through mature B cells but not on stem cells or plasma cells; it associates with calcium flux and B-cell activation and is a validated marker and target across B-cell malignancies. A CD3xCD20 bispecific bridges a CD20-positive B cell to a T cell, forming an immunological synapse that drives polyclonal T-cell-mediated killing of the target cell.

REGN 1979

Detects human CD3/CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Odronextamab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Odronextamab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Odronextamab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Odronextamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Odronextamab that binds human CD3 + CD20.